SCHEMBL6443183

SCHEMBL6443183

Cc1ccoc1-c1nc(N)nc(OCc2ccccn2)c1C#N

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MGMT P16455 1/20 0.42
TLR7 Q9NYK1 5/20 0.41
TLR8 Q9NR97 1/20 0.37
ADORA2A P29274 8/20 0.37
ADORA1 P30542 8/20 0.37
ADORA3 P0DMS8 1/20 0.37
KCNH2 Q12809 1/20 0.36
MAPK14 Q16539 1/20 0.36
SYK P43405 2/20 0.35
AURKB Q96GD4 2/20 0.35
INCENP Q9NQS7 2/20 0.35
ADORA2B P29275 1/20 0.35
MPO P05164 1/20 0.35
PIK3CD O00329 1/20 0.35
NOS3 P29474 1/20 0.34
NOS1 P29475 1/20 0.34
NOS2 P35228 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5041663 0.82 ADORA2A (0.56) MGMTADORA2AADORA1ADORA3ADORA2B
SCHEMBL6441414 0.81 MGMT (0.55) MGMTTLR7TLR8ADORA2AADORA1
SCHEMBL5039926 0.80 ADORA2A (0.52) MGMTTLR7TLR8ADORA2AADORA1
SCHEMBL6443675 0.80 MGMT (0.48) MGMTTLR7TLR8ADORA2AADORA1
SCHEMBL5041645 0.80 ADORA1 (0.57) MGMTADORA2AADORA1ADORA2B
SCHEMBL6443053 0.78 ADORA2A (0.60) MGMTADORA2AADORA1SYKAURKB
SCHEMBL5044782 0.76 ADORA2A (0.56) MGMTADORA2AADORA1ADORA3ADORA2B
SCHEMBL6444458 0.76 MGMT (0.42) MGMTTLR7TLR8ADORA2AADORA1
SCHEMBL6443037 0.76 SQOR (0.51) MGMTTLR7TLR8ADORA2AADORA1
SCHEMBL6441885 0.76 MGMT (0.53) MGMTTLR7TLR8ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
CN-1438890-A Adenosine receptor modulators HOFFMANNLA ROCHE AG F (CH) 2003-08-27 CN disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 MGMT 3075/4885TLR7 1772/4885TLR8 2074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.